307 related articles for article (PubMed ID: 34977518)
1. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis.
Nahon P; Najean M; Layese R; Zarca K; Segar LB; Cagnot C; Ganne-Carrié N; N'Kontchou G; Pol S; Chaffaut C; Carrat F; Ronot M; Audureau E; Durand-Zaleski I; ; ; ;
JHEP Rep; 2022 Jan; 4(1):100390. PubMed ID: 34977518
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.
Kim HL; An J; Park JA; Park SH; Lim YS; Lee EK
Hepatology; 2019 Apr; 69(4):1599-1613. PubMed ID: 30365164
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.
Decharatanachart P; Pan-Ngum W; Peeraphatdit T; Tanpowpong N; Tangkijvanich P; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
Gut Liver; 2024 Jan; 18(1):135-146. PubMed ID: 37560799
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score C-Triggered Abbreviated MRI.
Mulgaonkar A; Huang DQ; Siddiqi H; Fowler K; Sirlin CB; Marks R; Loomba R; Konijeti GG
Am J Gastroenterol; 2024 Feb; ():. PubMed ID: 38146873
[TBL] [Abstract][Full Text] [Related]
6. Study protocol for FASTRAK: a randomised controlled trial evaluating the cost impact and effectiveness of FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer.
Nahon P; Ronot M; Sutter O; Natella PA; Baloul S; Durand-Zaleski I; Audureau E
BMJ Open; 2024 Feb; 14(2):e083701. PubMed ID: 38367972
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
8. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.
Andersson KL; Salomon JA; Goldie SJ; Chung RT
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1418-24. PubMed ID: 18848905
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
11. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.
Goossens N; Singal AG; King LY; Andersson KL; Fuchs BC; Besa C; Taouli B; Chung RT; Hoshida Y
Clin Transl Gastroenterol; 2017 Jun; 8(6):e101. PubMed ID: 28640287
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
Parikh ND; Singal AG; Hutton DW; Tapper EB
Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Grutters J; Redekop K; Armstrong N; Lee K; Gloy V; Raatz H; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2013 Apr; 17(16):1-243. PubMed ID: 23611316
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Jackson S; Ryder S; Cramp M; Stein K
Br J Cancer; 2008 Apr; 98(7):1166-75. PubMed ID: 18382459
[TBL] [Abstract][Full Text] [Related]
17. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
Audureau E; Carrat F; Layese R; Cagnot C; Asselah T; Guyader D; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Chazouillères O; Mallat A; Grangé JD; Attali P; d'Alteroche L; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Pol S; Nahon P;
J Hepatol; 2020 Dec; 73(6):1434-1445. PubMed ID: 32615276
[TBL] [Abstract][Full Text] [Related]
18. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018.
Khatri G; Pedrosa I; Ananthakrishnan L; de Leon AD; Fetzer DT; Leyendecker J; Singal AG; Xi Y; Yopp A; Yokoo T
J Magn Reson Imaging; 2020 Feb; 51(2):415-425. PubMed ID: 31209978
[TBL] [Abstract][Full Text] [Related]
19. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.
Nguyen ALT; Si L; Lubel JS; Shackel N; Yee KC; Wilson M; Bradshaw J; Hardy K; Palmer AJ; Blizzard CL; de Graaff B
BMC Health Serv Res; 2023 Apr; 23(1):378. PubMed ID: 37076870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
